UCB has licensed exclusive worldwide rights to tozadenant, a selective inhibitor of the adenosine 2a receptor, currently in development at Biotie Therapies for the treatment of Parkinson's disease.
This represents an agreement to an earlier collaborative deal between the companies that was signed in 2010 and will provide Biotie with greater financial resources to carry out phase III trials of the promising compound.
A phase IIb study evaluating the safety and efficacy of tozadenant as an adjunctive therapy in levodopa-treated Parkinson's patients delivered positive top-line results, while patient enrolment for the phase III trial is expected to commence in the first half of 2015.
Professor Dr Iris Loew-Friedrich, chief medical officer and executive vice-president of UCB, said: "With the addition of the novel compound tozadenant to UCB's development portfolio, we should be able to further contribute to the advancement of the treatment and care for people living with Parkinson's disease."
This comes after UCB agreed a new collaboration with ConfometRx in the field of neuroscience earlier this month.See all the latest jobs in Pharmaceutical